HUMA Live signaler | Maksimer profitt med Getagraph.com

SELG 150897 min ago

@ $3.93

Utstedt: 14 feb 2024 @ 15:30

Avkastning: 90.59%

Forrige signal: feb 13 - 18:18

Forrige signal: Kjøp

Avkastning: 2.88 %

Live Chart Being Loaded With Signals

Commentary (28 mai 2024 @ 22:00):

Stats
Dagens volum	1.49M
Gjennomsnittsvolum	1.82M
Markedsverdi	891.94M
EPS	$0 ( 2024-05-10 )
Neste inntjeningsdato	( $-0.230 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.49
ATR14	$0.0160 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Wallace Max N.	Buy	4 015	Common Stock
2024-05-20	Wallace Max N.	Buy	3 990	Common Stock
2024-05-20	Green Charles Bruce	Sell	600	Stock Options (right to buy)
2024-05-20	Green Charles Bruce	Buy	600	Common Stock
2024-05-17	Green Charles Bruce	Sell	600	Stock Options (right to buy)

INSIDER POWER
-72.58
Last 98 transactions
Buy: 5 300 522 \| Sell: 38 284 441

Volum Korrelasjon

Lang: 0.51 (weak)

Kort: 0.38 (neutral)

Signal:(49.027) Neutral

Humacyte, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Humacyte, Inc. Korrelasjon - Valuta/Råvare

-0.28
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.07
( neutral )

-0.55
( weak negative )

0.76
( moderate )

Humacyte, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2023
Omsetning:	$0
Bruttogevinst:	$-7.72M (0.00 %)
EPS:	$-1.070

FY	2022
Omsetning:	$1.57M
Bruttogevinst:	$-6.69M (-427.48 %)
EPS:	$0.620

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Humacyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.